ホーム › トリプルネガティブ乳がん › カリフォルニア州
カリフォルニア州におけるトリプルネガティブ乳がんの臨床試験
カリフォルニア州内の拠点で、トリプルネガティブ乳がんに関する53件の研究が参加者を募集しています。
カリフォルニア州内の都市
- Los Angeles27件の研究
- San Diego13件の研究
- San Francisco11件の研究
- Baldwin Park10件の研究
- Mountain View8件の研究
- Irvine6件の研究
- Newport Beach6件の研究
- Santa Monica6件の研究
- Orange4件の研究
- Sacramento3件の研究
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of California - Los Angeles, Los Angeles
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank
- Community Cancer Institute ( Site 0100), Clovis
- Providence Medical Foundation ( Site 0080), Fullerton
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- MemorialCare Orange Coast Medical Center ( Site 9501), Fountain Valley
- Scripps Cancer Center ( Site 0052), La Jolla
- Kaiser Permanente - Oakland ( Site 0079), Oakland
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- City of Hope ( Site 0097), Duarte
- City of Hope Lennar Foundation Cancer Center ( Site 0099), Irvine
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, Santa Monica
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
- Scripps Clinic Torrey Pines - La Jolla, San Diego
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07339176Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Beverly Hills Cancer Center, Beverly Hills
- City of Hope Cancer Center, Duarte
- University of California Irvine Medical Center, Orange
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- City of Hope, Duarte
- Hoag Memorial Hospital Presbyterian, Irvine
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Ellison Institute of Technology (EITM), Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06353997Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Alta Bates Summit Medical Center, Berkeley
- PIH Health Whittier Hospital, Downey
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
- 他6件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- PIH Health Whittier Hospital, Whittier
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- City of Hope, Duarte
- UC San Diego Moores Cancer Center, La Jolla
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Community Cancer Institute, Clovis
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04895709Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- USC Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/13更新 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- Cedars Sinai Medical Center, Los Angeles
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06526819Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
- Stanford University, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT04768426A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Helios Clinical Research, Cerritos
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- 他2件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- City of Hope at Arcadia, Arcadia
- City of Hope Medical Center, Duarte
- City of Hope at Seacliff, Huntington Beach
- 他8件
被験者募集中
18歳以上 · 女性 · 2026/08/10更新 · NCT07741968Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT05318469Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of California Los Angeles Medical Center, Los Angeles
- University of California, San Diego; Moores Cancer Center, San Diego
- USOR Sansum Clinic, Santa Barbara
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
- Huntington Cancer Center, an Affiliate of CS Cancer, Pasadena
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07017673Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University of California LA, Los Angeles
- Stanford University Medical Center, Palo Alto
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07318805A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
- University of California Davis Comprehensive Cancer Center, Sacramento
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/17更新 · NCT07064018A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
- UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- City of Hope National Medical Center /ID# 276272, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403A Study of LY4175408 in Participants With Advanced Cancer
- Stanford Medicine Cancer Center, Stanford
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT06545331ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
- University of California, San Francisco, San Francisco
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/11更新 · NCT06224673Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Start Lacn, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT07517198A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Stanford Women's Cancer Center, Palo Alto
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04300556A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
- USC / Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第1相
18歳以上 · 女性 · 2026/05/19更新 · NCT05989828I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of California - Davis, Comprehensive Cancer Center, Davis
- City of Hope, Duarte
- University of California San Diego, La Jolla
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- University of California San Francisco, San Francisco
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/04更新 · NCT04434040Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第2相
18歳以上 · 女性 · 2026/04/20更新 · NCT05491226ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。